Throughout GSK, we understand that our impact has the potential to substantially change the lives of patients. This is particularly felt in R&D and our strategy is built on identifying the next generation of transformational medicines to maximise patient survival.
For many years, GSK’s research and development has focused on using cutting-edge innovation to develop potential treatments for cancer patients. Developing a new medicine often takes several years. That’s why our strategic approach to R&D took advantage of the rapid advances in science and technology to identify novel targets, mechanisms, and potential medicines to fuel the next wave of innovative medicines for patients.
In oncology, our work takes on new meaning as we are not only discovering and developing medicines to treat cancer, we are also an active part of the cancer community and understand the areas in which the need for novel treatments is greatest. At GSK, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer.
From research to trials to launch and beyond, patients and treating physicians are our partners and guideposts in R&D. We are actively seeking input and feedback from the patient and scientific communities to ensure the therapies we are developing are providing solutions for unmet needs. We believe leveraging the power of patient-driven science and technology will lead to more innovative and effective treatments.